


Fixed Interest Review 4th Quarter 2020



MARKET COMMENTARY

Recovery in the global economy was impeded by concerns of second and third Covid-19 waves spreading throughout the globe. The development of vaccines and the election of a new president in the United States lent support to the risk-on trade benefitting emerging markets in general. Although the US stimulus package was only signed into effect very late in the quarter, the finalisation of the post-Brexit agreement helped to keep the risk-on trade alive for most of the period. As post-election uncertainty dissipated, US bond yields reversed their decline, with the 10-year generic US yield increasing to 0.92% by the end of December. European yields retained their negative bias, however, with the German 10-year generic yield ending the quarter at -0.57% and its French counterpart closing at -0.34%.

The local fixed interest environment was not immune to the negative sentiment surrounding the Covid-19 pandemic. After some initial weakness, foreigners turned buyers as the risk-on trade escalated. The South African Medium-Term Budget Policy Statement (MTBPS) presented in October once again emphasised the ailing fiscal position, the contentious nature and existence of the State-Owned Enterprises and further deterioration in government's debt to GDP. Risks to the South Africa's economic outlook include: weaker than expected growth, continued deterioration in public finances, the failure to implement structural reforms and the threat of a second and third wave of COVID-19 infections. It is, therefore, vital that government implement the interventions of its

reconstruction and development plan to boost confidence and increase competitiveness should we wish to return to economic growth, and public finances are sustainable. We now turn our attention to upcoming events, such as the February budget and impending ratings reviews.

Inflation-linked bonds had a reasonable quarter as some upward pressure in the food sector lifted inflation measurements, albeit to a limited degree.

The Rand continued to strengthen over the quarter fuelled by the global risk-on trade on the back of progress being made in the implementation of Covid-19 vaccines. From a high of USD/ZAR 16.76 at the start of the period, the local currency ended the year around USD/ZAR 14.69.

Money market yields stabilised over the quarter as no further rate cuts were enacted by the SA Reserve Bank monetary policy committee. Borrowing costs remain low as the effects of the Covid-19 pandemic linger in all aspects of the economy. The long end of the money market curve gave up some of its gains from the previous quarter as demand for this asset class abated.

The bond market (JSE All Bond Total Return Index) was up 6.71% for Q4 2020. Equity markets (represented by the JSE ALSI) were up 9.75% and Inflation Linked Bonds (JSE IGOV index) returned 5.37% for the quarter and cash returned 0.97% for the quarter.

The rolling 12 month returns for bonds were 8.65%, equities 7.00%, and ILBs 4.22% and cash returning 5.39%. »

CADIZ BCI MONEY MARKET FUND – The number one ranked South African money market fund over 1, 2, 3, 5, 7 and 10 years with an annualised yield of 7.58% from inception.

Source: Morningstar | Performance reported for A Class net of fees in ZAR as at 31/12/2020 (ASISA) South African IB Money Market, Inception: 01/03/2006 | Annualised return is the weighted average compound growth rate over the period measured | Benchmark: STeFi Composite ZAR, Category Rank is against the (ASISA) South African IB Money Market Category | Highest Annual Return 12.27%; Lowest Annual Return 5.58%

KEY CONTRIBUTORS AND DETRACTORS FROM PERFORMANCE:

Macro global factors such as the US elections dominated local market price action. This was reflected in fixed income returns over the last quarter of 2020. With the Medium-Term Budget Policy Statement (MTBPS) setting the tone at beginning of the quarter, it set a bearish bias for the yield curve.

The local bond market navigated an uncertain 'budget' month, with foreign investors continuing to sell South African Government Bonds (SAGB) in excess of R13bn. Our funds took advantage of the precarious pricing environment and increased its position in the 7–12-year bucket of the curve. This proved worthwhile as both nominal and inflation linkers outperformed their respective benchmarks for the month of October.

November was met with euphoria in all markets as the positive news of President-elect Biden swept emerging markets. Blue wave trade was what gave momentum in our local bond market, with the All-Bond Index (ALBI) returning +3.28% and Government Inflation-linked Index (IGOVI) delivering +2.02% for the month. Even with the sovereign facing a one notch downgrade from both Moody's and Fitch; the nominal yield curve flattened by 60bps with more appetite for ultra-long bonds. We continued our strategy by adding duration through longer-dated nominal bonds such as the R2048. This area of the curve outperformed the short end and had a positive contribution to performance.

Swinging from the highs of November, bond yields continued to initially rally with differentials in long-dated nominal bonds narrowing. Technical bond spreads such as

the R209/R186 gap recorded lows of 327bps this quarter. SAGB's found support from non-residents, with total inflow standing at R19.8bn in December. We continued our strategy of adding duration in the belly to ultra-long end of the linker curve such as I2025, I2046 and I2050.

What detracted from performance, however, was the short end of the real yield curve selling off marginally, while back end bonds rallied 40bps.

POSITIONING AND OUTLOOK:

We are looking for opportunity to extend nominal duration as value opens up in the medium-to-longer-end of the curve. Similarly, inflation-linked bonds may present an opportunity to participate in the longer end of the real yield curve, with potential inflationary pressures building. We intend to hold a cautious strategic position as we examine the impending event risks in the system, namely the National Budget, rating reviews and the Monetary Policy framework. •

Mediclinic International Resilient amidst a global pandemic

PROVIDING HIGH-QUALITY HEALTHCARE SERVICES

Mediclinic is one of the largest independent pan-EMEA (Europe, Middle East, and Africa) healthcare services groups, with leading market positions across all divisions. The group's core purpose is to deliver value for patients by providing high-quality, cost-effective, integrated healthcare services in such a way that the business will be regarded as the most respected and trusted provider of healthcare services in each of its markets. Founded in 1983 in South Africa, the Group has expanded significantly over time and currently has operating divisions in Switzerland, southern Africa (South Africa and Namibia) and the United Arab Emirates. Mediclinic also holds a 29.9% stake in Spire (based in the United Kingdom).

WHAT HAS COVID-19 MEANT FOR THE BUSINESS?

Revenue and profitability were significantly impacted in April 2020 by the sudden onset of Covid-19 related lockdown measures and the suspension of non-urgent elective surgical procedures, with the latter aimed at safeguarding hospital capacity and resources. From May 2020 onwards, trading rebounded, however, particularly in Switzerland and the United Arab Emirates as the initial peak of the pandemic passed. By contrast, in southern Africa the recovery has been more gradual due to the timing of the initial peak.

Paradoxically, although Covid-19 has impacted the short-term profitability of the group, the pandemic has highlighted and accelerated the global demand for quality healthcare. Ageing populations, a growing disease burden and digitalisation of healthcare are creating further opportunities for expansion and evolution across the continuum of care.

WHY DO WE LIKE MEDICLINIC?

In the space of a decade, Mediclinic transformed itself into a leading global hospital operator with approximately 70% of revenue currently generated



outside of southern Africa. Regulation acts as a barrier to entry for Mediclinic, as the business operates in a highly regulated industry. Economies of scope also apply to hospitals, and they are profitable only when there are good occupancy levels. Although increased competition poses a threat to how quickly the group can fill their beds, Mediclinic has a strong brand which assists in being the health provider of choice.

When looking at the quality of the business, management's success, financial risk, and the value of business, we believe that Mediclinic ticks the necessary boxes. In terms of financial risk, the Group has moderate financial risk with most of the debt financed in Switzerland, with high fixed assets and low cost of borrowing. Overall, management is seen as competent, despite poor capital allocation decisions with subsequent write downs/impairments made by Swiss management in the past. In response, Mediclinic has subsequently strengthened this management team.

IS 2021 THE YEAR FOR MEDICLINIC?

Over the past few years, Mediclinic International has been impacted by several setbacks. More recently, regulatory challenges in Switzerland have materially altered the outlook for the group. Although the full impact of the current pandemic is unknown, this period has allowed the business to accelerate certain elements of group strategy, such as digital transformation, that provides opportunities for additional expansion across the continuum of care and therefore driving long-term performance.

We believe that the pandemic provided a buying opportunity for Mediclinic International as the share price dropped to around R52 on 19 March 2020. As the Covid-19-related lockdown measures led to the suspension of non-urgent elective surgical procedures, we expect to see some support from the catch-up of deferred patient demand. We believe that Mediclinic is a high-quality business that offers an attractive payoff profile which should be able to provide superior returns to shareholders over the long term. •

Physical Address: Alphen Estate, Alphen Drive, Constantia 7848, Cape Town / www.cadiz.co.za

This document is confidential and issued for the information of the addressee and clients of Cadiz only. It is subject to copyright and may not be reproduced in whole or in part without the written permission of Cadiz. The information, opinions and recommendations contained herein are and must be construed solely as statements of opinion and not statements of fact. No warranty, expressed or implied, as to the accuracy, timeliness, completeness, merchantability or fitness for any particular purpose of any such recommendation or information is given or made by Cadiz in any form or manner whatsoever. Each recommendation or opinion must be weighed solely as one factor in any investment or other decision made by or on behalf of any user of the information contained herein and such user must accordingly make its own study and evaluation of each strategy/security that it may consider purchasing, holding or selling and should appoint its own investment or financial or other advisers to assist the user in reaching any decision. Cadiz will accept no responsibility of whatsoever nature in respect of the use of any statement, opinion, recommendation or information contained in this document.

This document is for information only and do not constitute advice or a solicitation for funds. Investors should note that the value of an investment is dependent on numerous factors including, but not limited to, share price fluctuations, interest and exchange rates and other economic factors. Performance is further affected by uncertainties such as changes in government policy, taxation and other legal or regulatory developments. Past performance provides no guarantee of future performance.

Cadiz Funds (Pty) Ltd (Reg. No. 2013/118580/07) is an authorized financial services provider (FSP 45442)

Boutique Collective Investments (RF) (Pty) Ltd ("BCI") is a registered Manager of the Boutique Collective Investments Scheme, approved in terms of the Collective Investments Schemes Control Act, No 45 of 2002 and is a full member of the Association for Savings and Investment SA.

Collective Investment Schemes in securities are generally medium to long term investments. The value of participatory interests may go up or down and past performance is not necessarily an indication of future performance. The Manager does not guarantee the capital or the return of a portfolio. Collective Investments are traded at ruling prices and can engage in borrowing and scrip lending. A schedule of fees, charges and maximum commissions is available on request. BCI reserves the right to close the portfolio to new investors and reopen certain portfolios from time to time in order to manage them more efficiently. Additional information, including application forms, annual or quarterly reports can be obtained from BCI, free of charge.

Performance figures quoted for the portfolio is from Morningstar, as at the date of this document for a lump sum investment, using NAV-NAV with income reinvested and do not take any upfront manager's charge into account. Income distributions are declared on the ex-dividend date. Actual investment performance will differ based on the initial fees charge applicable, the actual investment date, the date of reinvestment and dividend withholding tax.

A money market portfolio is not the same as a bank deposit account. The price is targeted at a constant value. The total return to the investor is made up of interest received and any gain or loss made on any particular instrument. In most cases the return will merely have the effect of increasing or decreasing the daily yield, but that in the case of abnormal losses it can have the effect of reducing the capital value of the portfolio. Excessive withdrawals from the portfolio may place the portfolio under liquidity pressures and in such circumstances a process of ring-fencing of withdrawal instructions and managed pay-outs over time may be followed. The yield is calculated using an annualised seven day rolling average.

Actual annual figures are available to the investor on request.

Investments in foreign securities may include additional risks such as potential constraints on liquidity and repatriation of funds, macroeconomic risk, political risk, foreign exchange risk, tax risk, settlement risk as well as potential limitations on the availability of market information.

Boutique Collective Investments (RF) Pty Ltd retains full legal responsibility for the third party named portfolio.

Although reasonable steps have been taken to ensure the validity and accuracy of the information in this document, BCI does not accept any responsibility for any claim, damages, loss or expense, however it arises, out of or in connection with the information in this document, whether by a client, investor or intermediary. This document should not be seen as an offer to purchase any specific product and is not to be construed as advice or guidance in any form whatsoever. Investors are encouraged to obtain independent professional investment and taxation advice before investing with or in any of BCI/the Manager's products.